Copyright
©2009 Baishideng.
World J Gastrointest Surg. Nov 30, 2009; 1(1): 21-25
Published online Nov 30, 2009. doi: 10.4240/wjgs.v1.i1.21
Published online Nov 30, 2009. doi: 10.4240/wjgs.v1.i1.21
Company | Device | Characteristics | Clinical experience & future plans |
HepaLife | Hepa-Mate™ (previously HepatAssist) | Cryopreserved porcine cells, treatment 3-6 h for 1-5 d, charcoal column, and centrifugal plasmapheresis. Cell mass previously 60 g, in future trial 160 g | Phase II/III with HepatAssist in 171 ALF patients, only 9% improvement in OLT/NR as compared to controls. New trial in preparation |
Vital therapies | ELAD® | Two-chambered hollow fiber cartridge with immortalized human C3A cell line. Treatment up to 10 d. Ultrafiltrate perfusion. 4 replaceable cartridges. Cell mass 4 g × 200 g | Controlled study with 25 ALF patients completed. 92% recovery OLT/NR. Controlled clinical trial in 49 AoCLD patients in China |
Beijing and Nanjing Universities | TECA-BALSS/HBAL | Porcine cells (10-20 billion cells), outside compartment of hollow fiber devices | Phase I, 15 patients ALF and 3 patients AoCLD |
Hep-Art | AMC-BAL | Perfused scaffold, oxygenation in situ, 10-15 billion freshly isolated SPF porcine hepatocytes | Phase I/IIa; 14 ALF patients. Safe, no PERV transmission |
- Citation: Chamuleau RA. Future of bioartificial liver support. World J Gastrointest Surg 2009; 1(1): 21-25
- URL: https://www.wjgnet.com/1948-9366/full/v1/i1/21.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v1.i1.21